BT3 Biotime

Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences

Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences

NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that President and CEO Howard Federoff, M.D., Ph.D. is scheduled to present at the following virtual conferences:

Benzinga Global Small Cap Conference: December 8 – 9, 2021

  • Dr. Federoff will deliver his corporate presentation on Wednesday, December 8 at 4:40 PM EST.



  • Management will be available for one-on-one meetings to be held throughout the conference.



  • Investors can register here:

MedInvest Oncology Investor Conference: December 7 – 10, 2021

  • Dr. Federoff will deliver his corporate presentation on Thursday, December 9 at 11:20 AM EST.



  • Management will be available for one-on-one meetings to be held throughout the conference.



  • Investors can register here:

About Brooklyn ImmunoTherapeutics

Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases.

Brooklyn’s most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information about Brooklyn and its clinical programs, please visit .

Investor Relations Contact:

CORE IR

516-222-2560

Media Contact:

Jules Abraham

CORE IR

917-885-7378



EN
02/12/2021

Underlying

BT3Biotime

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biotime

 PRESS RELEASE
Free
BT3 BIOTIME

Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeuti...

Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s shares to trade under new ticker symbol “ERNA” starting on October 17, 2022, and a one-for-twenty share consolidation will become effective on that date SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeuti...

October 11, 2022 1 EN
 PRESS RELEASE
Free
BT3 BIOTIME

Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-...

Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. The primary endpoint of the study was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2. One hundred and fifty patients were enrolled ...

July 26, 2022 1 EN
 PRESS RELEASE
Free
BT3 BIOTIME

Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification R...

Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today announced that on June 17, 2022, it received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per share under the Nasdaq...

June 17, 2022 1 EN
 PRESS RELEASE
Free
BT3 BIOTIME

Brooklyn ImmunoTherapeutics Announces Board Changes

Brooklyn ImmunoTherapeutics Announces Board Changes SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the following appointments to the Board, effective June 5, 2022: Matt Angel, Ph.D., Interim Chief Executive Officer (“CEO”) of Brooklyn and Co-Founder, Chairman, President and CEO of Factor Bioscience Inc.Gregory Fiore, Co-Fo...

June 7, 2022 1 EN
 PRESS RELEASE
Free
BT3 BIOTIME

Brooklyn ImmunoTherapeutics Announces Changes to Executive Management:...

Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chai...

May 31, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch